Anebulo Pharma up on cannabis intoxication drug trial data

Anebulo Pharmaceuticals

26/09/2022 16:17

** Shares of Anebulo Pharmaceuticals Inc  ANEB.O  rise 5% to
$2.95
    ** Company says its experimental drug, ANEB-001, reduced
negative effects induced by a key cannabis component in one part
of a mid-stage trial  urn:newsml:reuters.com:*:nBw8MP8s2a
    ** Two dosage level groups in the trial were given twice the
dose of component, tetrahydrocannabinol (THC), and lower doses
of ANEB-001, compared to the other part of the trial, which was
done earlier 
    ** Says data from the drug's 10mg dosage group is "even more
impressive" considering the doubled THC dose
    ** Adds that it is currently exploring the effects of
delayed dosing of the drug to better understand real-world
conditions
    ** Including session's gain, stock down 52% YTD
 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com))